Codexis (CDXS) Competitors

Rigel Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, Rigel Pharmaceuticals had 6 more articles in the media than Codexis. MarketBeat recorded 6 mentions for Rigel Pharmaceuticals and 0 mentions for Codexis. Rigel Pharmaceuticals' average media sentiment score of 0.30 beat Codexis' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Rigel Pharmaceuticals has a net margin of 121.50% compared to Codexis' net margin of -40.97%. Rigel Pharmaceuticals' return on equity of 47.99% beat Codexis' return on equity.

Rigel Pharmaceuticals has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, Codexis has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market.

Rigel Pharmaceuticals presently has a consensus price target of $54.50, suggesting a potential upside of 28.05%. Codexis has a consensus price target of $5.00, suggesting a potential upside of 92.31%. Given Codexis' higher probable upside, analysts plainly believe Codexis is more favorable than Rigel Pharmaceuticals.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ironwood Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Codexis' net margin of -40.97%. Ironwood Pharmaceuticals' return on equity of -39.65% beat Codexis' return on equity.

78.5% of Codexis shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Codexis currently has a consensus target price of $5.00, indicating a potential upside of 92.31%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 39.45%. Given Codexis' higher possible upside, analysts plainly believe Codexis is more favorable than Ironwood Pharmaceuticals.

Codexis has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market.

In the previous week, Ironwood Pharmaceuticals had 3 more articles in the media than Codexis. MarketBeat recorded 3 mentions for Ironwood Pharmaceuticals and 0 mentions for Codexis. Ironwood Pharmaceuticals' average media sentiment score of 1.21 beat Codexis' score of 0.00 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

In the previous week, Achieve Life Sciences' average media sentiment score of 0.00 equaled Codexis'average media sentiment score.

33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Achieve Life Sciences presently has a consensus price target of $16.00, suggesting a potential upside of 145.40%. Codexis has a consensus price target of $5.00, suggesting a potential upside of 92.31%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Codexis.

Achieve Life Sciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, Codexis has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

Achieve Life Sciences has a net margin of 0.00% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Achieve Life Sciences' return on equity.

Codexis has higher revenue and earnings than Achieve Life Sciences. Codexis is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Codexis currently has a consensus target price of $5.00, indicating a potential upside of 92.31%. Myriad Genetics has a consensus target price of $6.50, indicating a potential upside of 10.92%. Given Codexis' higher probable upside, equities analysts plainly believe Codexis is more favorable than Myriad Genetics.

78.5% of Codexis shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Codexis has a net margin of -40.97% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Codexis' return on equity.

In the previous week, Myriad Genetics had 4 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Myriad Genetics and 0 mentions for Codexis. Myriad Genetics' average media sentiment score of 0.51 beat Codexis' score of 0.00 indicating that Myriad Genetics is being referred to more favorably in the news media.

Codexis has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market.

Codexis has higher earnings, but lower revenue than Myriad Genetics. Codexis is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.